Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00451451




Registration number
NCT00451451
Ethics application status
Date submitted
21/03/2007
Date registered
23/03/2007
Date last updated
26/01/2015

Titles & IDs
Public title
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
Scientific title
A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
Secondary ID [1] 0 0
109MS302
Universal Trial Number (UTN)
Trial acronym
CONFIRM
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Relapsing-Remitting Multiple Sclerosis 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: BG00012 240 mg Twice Daily (BID) - Participants received two 120 mg BG00012 capsules orally twice daily (BID) and two placebo capsules orally once daily (QD)

Experimental: BG00012 240 mg 3 Times Daily (TID) - Participants received two 120 mg BG00012 capsules orally three times daily (TID)

Placebo comparator: Placebo - Participants received two placebo capsules orally three times daily (TID)

Active comparator: Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD) - Participants received glatiramer acetate (GA) 20 mg subcutaneous injection once daily (QD)
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annualized Relapse Rate
Timepoint [1] 0 0
2 years
Secondary outcome [1] 0 0
Number of New or Newly Enlarging T2 Hyperintense Lesions
Timepoint [1] 0 0
2 years
Secondary outcome [2] 0 0
Number of New T1 Hypointense Lesions
Timepoint [2] 0 0
2 years
Secondary outcome [3] 0 0
Proportion of Subjects Relapsed
Timepoint [3] 0 0
2 years
Secondary outcome [4] 0 0
Proportion of Subjects Experiencing Progression of Disability Assessed Using the Expanded Disability Status Scale (EDSS)
Timepoint [4] 0 0
2 years

Eligibility
Key inclusion criteria
Unless otherwise specified, to be eligible to participate in this study, candidates must meet the following eligibility criteria at the time of the randomization:

Key

* Must have confirmed diagnosis of RRMS according to McDonald criteria #1-4
* Must have a baseline EDSS between 0.0 and 5.0, inclusive.
* Must have relapsing-remitting disease course.

Key
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Other chronic disease of immune system, malignancies, urologic, pulmonary, gastrointestinal disease
* Pregnant or nursing women

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/06/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/08/2011
Sample size
Target
Accrual to date
Final
1417
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Massachusetts
Country [14] 0 0
United States of America
State/province [14] 0 0
Michigan
Country [15] 0 0
United States of America
State/province [15] 0 0
New Hampshire
Country [16] 0 0
United States of America
State/province [16] 0 0
New Jersey
Country [17] 0 0
United States of America
State/province [17] 0 0
New York
Country [18] 0 0
United States of America
State/province [18] 0 0
North Carolina
Country [19] 0 0
United States of America
State/province [19] 0 0
Ohio
Country [20] 0 0
United States of America
State/province [20] 0 0
Oklahoma
Country [21] 0 0
United States of America
State/province [21] 0 0
Oregon
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
Tennessee
Country [24] 0 0
United States of America
State/province [24] 0 0
Texas
Country [25] 0 0
United States of America
State/province [25] 0 0
Utah
Country [26] 0 0
United States of America
State/province [26] 0 0
Vermont
Country [27] 0 0
United States of America
State/province [27] 0 0
Virginia
Country [28] 0 0
United States of America
State/province [28] 0 0
Washington
Country [29] 0 0
United States of America
State/province [29] 0 0
Wisconsin
Country [30] 0 0
Belarus
State/province [30] 0 0
Gomel
Country [31] 0 0
Belarus
State/province [31] 0 0
Minsk
Country [32] 0 0
Belarus
State/province [32] 0 0
Vitebsk
Country [33] 0 0
Belgium
State/province [33] 0 0
Lommel
Country [34] 0 0
Belgium
State/province [34] 0 0
Sijsele-Damme
Country [35] 0 0
Belgium
State/province [35] 0 0
Woluwe
Country [36] 0 0
Bosnia and Herzegovina
State/province [36] 0 0
B&H Federation
Country [37] 0 0
Bosnia and Herzegovina
State/province [37] 0 0
Republic Srpska
Country [38] 0 0
Bosnia and Herzegovina
State/province [38] 0 0
Sarajevo B&H Federation
Country [39] 0 0
Bulgaria
State/province [39] 0 0
Plovdiv
Country [40] 0 0
Bulgaria
State/province [40] 0 0
Rousse
Country [41] 0 0
Bulgaria
State/province [41] 0 0
Sofia
Country [42] 0 0
Bulgaria
State/province [42] 0 0
Stara Zagora
Country [43] 0 0
Bulgaria
State/province [43] 0 0
Varna
Country [44] 0 0
Canada
State/province [44] 0 0
Edmonton
Country [45] 0 0
Canada
State/province [45] 0 0
London
Country [46] 0 0
Canada
State/province [46] 0 0
Montreal
Country [47] 0 0
Canada
State/province [47] 0 0
Osijek
Country [48] 0 0
Costa Rica
State/province [48] 0 0
San Jose
Country [49] 0 0
Croatia
State/province [49] 0 0
Rijeka
Country [50] 0 0
Croatia
State/province [50] 0 0
Zagreb
Country [51] 0 0
Czech Republic
State/province [51] 0 0
Ostrava-Moravska
Country [52] 0 0
Czech Republic
State/province [52] 0 0
Ostrava
Country [53] 0 0
Czech Republic
State/province [53] 0 0
Praha
Country [54] 0 0
Estonia
State/province [54] 0 0
Kuressaare
Country [55] 0 0
Estonia
State/province [55] 0 0
Parnu
Country [56] 0 0
Estonia
State/province [56] 0 0
Tallinn
Country [57] 0 0
Estonia
State/province [57] 0 0
Tartu
Country [58] 0 0
France
State/province [58] 0 0
Caen
Country [59] 0 0
France
State/province [59] 0 0
Dijon
Country [60] 0 0
France
State/province [60] 0 0
Marseille
Country [61] 0 0
France
State/province [61] 0 0
Montpellier
Country [62] 0 0
France
State/province [62] 0 0
Nancy
Country [63] 0 0
France
State/province [63] 0 0
Nimes
Country [64] 0 0
France
State/province [64] 0 0
Strasbourg
Country [65] 0 0
Germany
State/province [65] 0 0
Bamberg
Country [66] 0 0
Germany
State/province [66] 0 0
Bayreuth
Country [67] 0 0
Germany
State/province [67] 0 0
Berg Starnberger
Country [68] 0 0
Germany
State/province [68] 0 0
Berlin
Country [69] 0 0
Germany
State/province [69] 0 0
Dusseldorf
Country [70] 0 0
Germany
State/province [70] 0 0
Erbach
Country [71] 0 0
Germany
State/province [71] 0 0
Erlangen
Country [72] 0 0
Germany
State/province [72] 0 0
Giessen
Country [73] 0 0
Germany
State/province [73] 0 0
Halle (Saale)
Country [74] 0 0
Germany
State/province [74] 0 0
Hanburg
Country [75] 0 0
Germany
State/province [75] 0 0
Heidelberg
Country [76] 0 0
Germany
State/province [76] 0 0
Koln
Country [77] 0 0
Germany
State/province [77] 0 0
Magdeburg
Country [78] 0 0
Germany
State/province [78] 0 0
Marburg
Country [79] 0 0
Germany
State/province [79] 0 0
Munchen
Country [80] 0 0
Germany
State/province [80] 0 0
Regensburg
Country [81] 0 0
Germany
State/province [81] 0 0
Schwerin
Country [82] 0 0
Greece
State/province [82] 0 0
Athens
Country [83] 0 0
Greece
State/province [83] 0 0
Larisa
Country [84] 0 0
Greece
State/province [84] 0 0
Patra
Country [85] 0 0
Greece
State/province [85] 0 0
Thessaloniki
Country [86] 0 0
India
State/province [86] 0 0
Ahmedabad
Country [87] 0 0
India
State/province [87] 0 0
Bangalore
Country [88] 0 0
India
State/province [88] 0 0
Calicut
Country [89] 0 0
India
State/province [89] 0 0
Chandigarh
Country [90] 0 0
India
State/province [90] 0 0
Chennai
Country [91] 0 0
India
State/province [91] 0 0
Cochin
Country [92] 0 0
India
State/province [92] 0 0
Coimbatore
Country [93] 0 0
India
State/province [93] 0 0
Kochi
Country [94] 0 0
India
State/province [94] 0 0
Kolkata
Country [95] 0 0
India
State/province [95] 0 0
Lucknow
Country [96] 0 0
India
State/province [96] 0 0
Ludhiana
Country [97] 0 0
India
State/province [97] 0 0
Mangalore
Country [98] 0 0
India
State/province [98] 0 0
Mumbai
Country [99] 0 0
India
State/province [99] 0 0
New Delhi
Country [100] 0 0
India
State/province [100] 0 0
Pune
Country [101] 0 0
Ireland
State/province [101] 0 0
Cork
Country [102] 0 0
Ireland
State/province [102] 0 0
Dublin
Country [103] 0 0
Ireland
State/province [103] 0 0
Galway
Country [104] 0 0
Israel
State/province [104] 0 0
Holon
Country [105] 0 0
Israel
State/province [105] 0 0
Safed
Country [106] 0 0
Latvia
State/province [106] 0 0
Riga
Country [107] 0 0
Macedonia, The Former Yugoslav Republic of
State/province [107] 0 0
Skopje
Country [108] 0 0
Mexico
State/province [108] 0 0
Jal
Country [109] 0 0
Mexico
State/province [109] 0 0
Michoacan
Country [110] 0 0
Mexico
State/province [110] 0 0
Nuevo Leon
Country [111] 0 0
Mexico
State/province [111] 0 0
Aguascalientes
Country [112] 0 0
Mexico
State/province [112] 0 0
Guadalajara
Country [113] 0 0
Mexico
State/province [113] 0 0
Mexico DF
Country [114] 0 0
Mexico
State/province [114] 0 0
Mexico
Country [115] 0 0
Mexico
State/province [115] 0 0
Monterray
Country [116] 0 0
Moldova, Republic of
State/province [116] 0 0
Chisinau
Country [117] 0 0
Moldova, Republic of
State/province [117] 0 0
Kishinev
Country [118] 0 0
New Zealand
State/province [118] 0 0
Hamilton
Country [119] 0 0
Poland
State/province [119] 0 0
Bialystok
Country [120] 0 0
Poland
State/province [120] 0 0
Gdansk
Country [121] 0 0
Poland
State/province [121] 0 0
Katowice
Country [122] 0 0
Poland
State/province [122] 0 0
Lodz
Country [123] 0 0
Poland
State/province [123] 0 0
Lublin
Country [124] 0 0
Poland
State/province [124] 0 0
Poznan
Country [125] 0 0
Poland
State/province [125] 0 0
Szczecin
Country [126] 0 0
Poland
State/province [126] 0 0
Warsaw
Country [127] 0 0
Poland
State/province [127] 0 0
Warszawa
Country [128] 0 0
Poland
State/province [128] 0 0
Wroclaw
Country [129] 0 0
Puerto Rico
State/province [129] 0 0
Guaynabo
Country [130] 0 0
Romania
State/province [130] 0 0
Bucuresti
Country [131] 0 0
Romania
State/province [131] 0 0
Iasi
Country [132] 0 0
Romania
State/province [132] 0 0
Oradea
Country [133] 0 0
Romania
State/province [133] 0 0
Tirgu Mures
Country [134] 0 0
Romania
State/province [134] 0 0
Tirgu-Mures
Country [135] 0 0
Serbia
State/province [135] 0 0
Belgrade
Country [136] 0 0
Serbia
State/province [136] 0 0
Kragujevac
Country [137] 0 0
Serbia
State/province [137] 0 0
Nis
Country [138] 0 0
Serbia
State/province [138] 0 0
Novi Sad
Country [139] 0 0
Slovakia
State/province [139] 0 0
Kosice
Country [140] 0 0
Slovakia
State/province [140] 0 0
Martin
Country [141] 0 0
Spain
State/province [141] 0 0
Barcelona
Country [142] 0 0
Spain
State/province [142] 0 0
Bilbao
Country [143] 0 0
Spain
State/province [143] 0 0
Cordoba
Country [144] 0 0
Spain
State/province [144] 0 0
Gandia
Country [145] 0 0
Spain
State/province [145] 0 0
Madrid
Country [146] 0 0
Spain
State/province [146] 0 0
Malaga
Country [147] 0 0
Spain
State/province [147] 0 0
Santiago de Compostela
Country [148] 0 0
Spain
State/province [148] 0 0
Sevilla
Country [149] 0 0
Ukraine
State/province [149] 0 0
Kharkiv
Country [150] 0 0
Ukraine
State/province [150] 0 0
Kyiv
Country [151] 0 0
Ukraine
State/province [151] 0 0
Lviv
Country [152] 0 0
Ukraine
State/province [152] 0 0
Odessa
Country [153] 0 0
Ukraine
State/province [153] 0 0
Poltava
Country [154] 0 0
Ukraine
State/province [154] 0 0
Simferopol
Country [155] 0 0
Ukraine
State/province [155] 0 0
Zaporozhye

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Biogen
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for MS to get worse.

Other objectives of the study are to determine the safety and tolerability of BG00012, as well as the effect it may have on tests and evaluations used to assess MS. Additionally, glatiramer acetate is being used to compare its benefits and risks with placebo and BG00012.
Trial website
https://clinicaltrials.gov/study/NCT00451451
Trial related presentations / publications
Gold R, Arnold DL, Bar-Or A, Fox RJ, Kappos L, Chen C, Parks B, Miller C. Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE. Ther Adv Neurol Disord. 2020 May 12;13:1756286420915005. doi: 10.1177/1756286420915005. eCollection 2020. Erratum In: Ther Adv Neurol Disord. 2020 Oct 21;13:1756286420968357. doi: 10.1177/1756286420968357.
Mehta D, Miller C, Arnold DL, Bame E, Bar-Or A, Gold R, Hanna J, Kappos L, Liu S, Matta A, Phillips JT, Robertson D, von Hehn CA, Campbell J, Spach K, Yang L, Fox RJ. Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice. Neurology. 2019 Apr 9;92(15):e1724-e1738. doi: 10.1212/WNL.0000000000007262. Epub 2019 Mar 27.
Fox RJ, Gold R, Phillips JT, Okwuokenye M, Zhang A, Marantz JL. Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM. Neurol Ther. 2017 Dec;6(2):175-187. doi: 10.1007/s40120-017-0077-5. Epub 2017 Aug 2.
Fernandez O, Giovannoni G, Fox RJ, Gold R, Phillips JT, Potts J, Okwuokenye M, Marantz JL. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM. Clin Ther. 2017 Aug;39(8):1671-1679. doi: 10.1016/j.clinthera.2017.06.012. Epub 2017 Jul 25.
Fox RJ, Chan A, Zhang A, Xiao J, Levison D, Lewin JB, Edwards MR, Marantz JL. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis. Curr Med Res Opin. 2017 Feb;33(2):175-183. doi: 10.1080/03007995.2016.1248380. Epub 2016 Nov 10.
Gold R, Giovannoni G, Phillips JT, Fox RJ, Zhang A, Marantz JL. Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. Neurol Ther. 2016 Jun;5(1):45-57. doi: 10.1007/s40120-016-0042-8. Epub 2016 Mar 1.
Giovannoni G, Gold R, Fox RJ, Kappos L, Kita M, Yang M, Sarda SP, Zhang R, Viglietta V, Havrdova E. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies. Clin Ther. 2015 Nov 1;37(11):2543-51. doi: 10.1016/j.clinthera.2015.09.011. Epub 2015 Oct 31.
Fox RJ, Kita M, Cohan SL, Henson LJ, Zambrano J, Scannevin RH, O'Gorman J, Novas M, Dawson KT, Phillips JT. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin. 2014 Feb;30(2):251-62. doi: 10.1185/03007995.2013.849236. Epub 2013 Oct 22.
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT; CONFIRM Study Investigators. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012 Sep 20;367(12):1087-97. doi: 10.1056/NEJMoa1206328. Erratum In: N Engl J Med. 2012 Oct 25;367(17):1673.
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Biogen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00451451